Chunwei W. Xu

305 Zhongshan Road
Nanjing, 210002, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 175 publications

Correction: Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.

Correction: Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: May 06, 2026

International Consensus on Severe Lung Cancer-The Second Edition.

International Consensus on Severe Lung Cancer-The Second Edition.

Journal: Translational lung cancer research

Published: March 21, 2026

Expert consensus on the detection and clinical application of tumor mutational burden.

Expert consensus on the detection and clinical application of tumor mutational burden.

Journal: Cancer biology & medicine

Published: February 18, 2026

FGF2-Based Cyclic Peptide PET Tracer for Noninvasive Detection of FGFR1 Expression in Non-Small Cell Lung Cancer.

FGF2-Based Cyclic Peptide PET Tracer for Noninvasive Detection of FGFR1 Expression in Non-Small Cell Lung Cancer.

Journal: Journal of medicinal chemistry

Published: February 17, 2026

Ligand-Based Computational Design and Preclinical Evaluation of a Novel Cyclic Peptide Radiotracer for FGFR1-Targeted PET Imaging in Uveal Melanoma.

Ligand-Based Computational Design and Preclinical Evaluation of a Novel Cyclic Peptide Radiotracer for FGFR1-Targeted PET Imaging in Uveal Melanoma.

Journal: ACS sensors

Published: February 09, 2026

The Prognostic Significance of BRCA1-Associated Protein 1(BAP1) in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis.

The Prognostic Significance of BRCA1-Associated Protein 1(BAP1) in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis.

Journal: Clinical Medicine Insights. Oncology

Published: January 10, 2026

Targeting of CDK1 and PRMT5 as a potential therapeutic combination for non-small cell lung cancer.

Targeting of CDK1 and PRMT5 as a potential therapeutic combination for non-small cell lung cancer.

Journal: Histology and histopathology

Published: January 05, 2026

Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.

Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: December 24, 2025

Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee.

Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 21, 2025

MET amplification in diffuse pleural mesothelioma and response to savolitinib: a case report.

MET amplification in diffuse pleural mesothelioma and response to savolitinib: a case report.

Journal: Translational lung cancer research

Published: November 18, 2025

Meta-analysis of liver venous deprivation vs portal vein embolization in treating liver cancer with an insufficient liver remnant.

Meta-analysis of liver venous deprivation vs portal vein embolization in treating liver cancer with an insufficient liver remnant.

Journal: Journal of the Chinese Medical Association : JCMA

Published: November 03, 2025

Inhibition of protein kinase CK2 remodels the tumor immune microenvironment and sensitizes lung cancer to PD-L1 blockade.

Inhibition of protein kinase CK2 remodels the tumor immune microenvironment and sensitizes lung cancer to PD-L1 blockade.

Journal: Experimental hematology & oncology

Published: October 28, 2025

Showing 1-12 of 175

Last Updated: 09/26/2026